Looking for a different way to manage diabetes care
Ultimately, it depends on what youre trying to treat, how your body responds, your metabolic state, and what your doctor thinks is best for you
Second, The Lancet issued an Expression of Concern regarding this trial in 2013 (PMID 23561987), following a regulatory audit that found adverse events were under-recorded at two of five study sites
Currently, most insurance coverage for GLP-1 RAs is limited to patients with type 2 diabetes, although their use for cardiovascular risk reduction in non-diabetic patients continues to gain support from clinical evidence [21]
At 10mg, that number rose to 89%
Im Done Measuring Progress by the Scale